The FDA’s hardest problem in cell and gene therapy has never been ambition; it is repetition. Programs tend to re-run the same manufacturing characterization, the same animal studies, the same early safety work, even when a sponsor or the field already knows the answer. On June 2, the agency issued draft guidance arguing that some of that work need not be done twice.
The draft outlines how sponsors of human gene therapy products that use genome editing in human somatic cells can lean on “existing scientific and regulatory knowledge” — publicly available information and established platform knowledge spanning chemistry, manufacturing and controls (CMC), nonclinical results and clinical data — to streamline submissions. The stated aim is to reduce “redundant testing” for patients with rare and life-threatening diseases.
Efficiency, not a lowered bar
CBER officials were careful to frame the move as procedural, not a relaxation of standards. “Leveraging prior knowledge does not mean lowering the bar; it means raising our collective efficiency while maintaining the highest standards of safety and efficacy,” said Vijay Kumar, acting director of CBER’s Office of Therapeutic Products. Acting CBER director Karim Mikhail tied the action to getting therapies to patients “faster.”
“In all cases, sponsors should provide a scientific rationale demonstrating the applicability of the data being leveraged.”
That caveat is the load-bearing one: reuse must be justified product by product. The guidance complements the agency’s Plausible Mechanism Framework and its recent draft on assessing off-target editing via next-generation sequencing. The FDA is also steering sponsors toward early engagement — INTERACT and pre-IND meetings — before an IND is filed.
This is a draft, not a binding rule. Comments are due within 90 days of Federal Register publication, after which the FDA says it will review them before finalizing.